Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
2018 · New England Journal of Medicine · 6,385 citations
https://doi.org/10.1056/nejmoa1801005
T
Takayasu Kurata
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
459
Papers
35.0K
Citations
59
h-index
180
i10-index
Takayasu Kurata is an academic researcher from Kansai Medical University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 59, co-authored 391 publications.
ORCID: 0000-0003-4123-3567Papers by this author
worksOsimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
2017 · New England Journal of Medicine · 5,025 citations
https://doi.org/10.1056/nejmoa1713137
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2019 · The Lancet · 3,270 citations
https://doi.org/10.1016/s0140-6736(18)32409-7
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
2021 · Journal of Thoracic Oncology · 455 citations
https://doi.org/10.1016/j.jtho.2020.12.015
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
2019 · Journal of Thoracic Oncology · 423 citations
https://doi.org/10.1016/j.jtho.2019.10.002
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
2021 · Annals of Oncology · 409 citations
https://doi.org/10.1016/j.annonc.2021.04.008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat